A multicenter photoprovocation study to identify potential biomarkers by global peptide profiling in cutaneous lupus erythematosus

Lupus

Volumn 24, Issue 13, 2015, Pages 1406-1420

  Calderon, C ^a   Zucht, H D ^b   Kuhn, A ^c   Wozniacka, A ^d   Szepietowski, J C ^e   Nyberg, F ^f   Weichenthal, M ^g   Piantone, A ^a   Budde, P ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Formerly of Digilab BioVisioN GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e WROCLAW MEDICAL UNIVERSITY   (Poland)

^f DANDERYD HOSPITAL   (Sweden)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Cutaneous lupus erythematosus; lupus erythematosus; peptides; peptidomics; photoprovocation

Indexed keywords

BETA 2 MICROGLOBULIN; BETA DEFENSIN 1; CD99 ANTIGEN; IMMUNOGLOBULIN KAPPA CHAIN; PEPTIDE; SECRETORY COMPONENT; BETA DEFENSIN; BIOLOGICAL MARKER; DEFB1 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; PEPTIDOMICS; PHOTOSENSITIVITY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN LUPUS ERYTHEMATOSUS; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET IRRADIATION; BIOPSY; BLOOD; CLINICAL TRIAL; METABOLISM; MULTICENTER STUDY; PATHOLOGY; PHOTOSENSITIVITY DISORDERS; RADIATION RESPONSE; SKIN; ULTRAVIOLET RADIATION;

BETA 2-MICROGLOBULIN; BETA-DEFENSINS; BIOMARKERS; BIOPSY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; PEPTIDES; PHOTOSENSITIVITY DISORDERS; SKIN; ULTRAVIOLET RAYS;

EID: 84945250227     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315596077     Document Type: Article

References (36)

1. Macleod JMH,. Lupus erythematosus: Some observations on its etiology. AMA Arch Dermatol Syphilol 1924; 9: 1-12.
2. Pusey WA,. Attacks of lupus erythematosus following exposure to sunlight or other weather factors. AMA Arch Dermatol Syphilol 1915; 33: 388-388.
3. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
4. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus: A 15-year experience. J Am Acad Dermatol 2001; 45: 86-95.
5. Ruland V, Haust M, Stilling RM, et al. Updated analysis of standardized photoprovocation in patients with cutaneous lupus erythematosus. Arthritis Care Res (Hoboken) 2013; 65: 767-776.
6. Kuhn A, Wozniacka A, Szepietowski JC, et al. Photoprovocation in cutaneous lupus erythematosus: A multicenter study evaluating a standardized protocol. J Invest Dermatol 2011; 131: 1622-1630.
7. Sanders CJ, Van Weelden H, Kazzaz GA, Sigurdsson V, Toonstra J, Bruijnzeel-Koomen CA,. Photosensitivity in patients with lupus erythematosus: A clinical and photobiological study of 100 patients using a prolonged phototest protocol. Br J Dermatol 2003; 149: 131-137.
8. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-1178.
9. Schulz-Knappe P, Zucht HD, Heine G, Jürgens M, Hess R, Schrader M,. Peptidomics: The comprehensive analysis of peptides in complex biological mixtures. Comb Chem High Throughput Screen 2001; 4: 207-217.
10. Schrader M, Budde P, Rose H, Lamping N, Schulz-Knappe P, Zucht HD, Peptidomics technologies and applications in drug research. In: Hamacher M, Marcus K, Stühler K, van Hall A, Warscheid B, Meyer HE, (eds). Proteomics in drug research, Weinheim: Wiley-VCH, 2006, pp. 113-135.
11. Schrader M, Schulz-Knappe P,. Peptidomics technologies for human body fluids. Trends Biotechnol 2001; 19: 55-60.
12. Liu K, Li QZ, Delgado-Vega AM, et al. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest 2009; 119: 911-923.
13. Ponticelli C, Meroni PL,. Kallikreins and lupus nephritis. J Clin Invest 2009; 119: 768-771.
14. Tammen H, Schulte I, Hess R, et al. Peptidomic analysis of human blood specimens: Comparison between plasma specimens and serum by differential peptide display. Proteomics 2005; 5: 3414-3422.
15. Traub F, Jost M, Hess R, et al. Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas. Lab Invest 2006; 86: 246-253.
16. Menzel C, Guillou V, Kellmann M, Khamenya V, Juergens M, Schulz-Knappe P,. High-throughput biomarker discovery and identification by mass spectrometry. Comb Chem High Throughput Screen 2005; 8: 743-755.
17. Wold S, Sjöströma M, Eriksson L,. PLS-regression: A basic tool of chemometrics. Chemometr Intell Lab Syst 2001; 58: 109-130.
18. Palermo G, Piraino P, Zucht HD,. Performance of PLS regression coefficients in selecting variables for each response of a multivariate PLS for omics-type data. Adv Appl Bioinform Chem 2009; 2: 57-70.
19. Zucht HD, Lamerz J, Khamenia V, et al. Datamining methodology for LC-MALDI-MS based peptide profiling. Comb Chem High Throughput Screen 2005; 8: 717-723.
20. Martens H, Naes T,. Multivariate calibration, Chichester: Wiley, 1989.
21. Jost MM, Lamerz J, Tammen H, et al. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochem Pharmacol 2009; 77: 228-237.
22. Casciola-Rosen LA, Anhalt G, Rosen A,. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179: 1317-1330.
23. Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C,. Advances in thymosin β10 research: Differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest 2009; 27: 1016-1022.
24. Oono T, Specks U, Eckes B, et al. Expression of type VI collagen mRNA during wound healing. J Invest Dermatol 1993; 100: 329-334.
25. Schnoor M, Cullen P, Lorkowski J, et al. Production of type VI collagen by human macrophages: A new dimension in macrophage functional heterogeneity. J Immunol 2008; 180: 5707-5719.
26. Dissanayake NS, Mason RS,. Modulation of skin cell functions by transforming growth factor-β1 and ACTH after ultraviolet irradiation. J Endocrinol 1998; 159: 153-163.
27. Blanch VJ, Piskurich JF, Kaetzel CS,. Cutting edge: Coordinate regulation of IFN regulatory factor-1 and the polymeric Ig receptor by proinflammatory cytokines. J Immunol 1999; 162: 1232-1235.
28. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY,. Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000; 85: 207-214.
29. Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995; 4: 29-32.
30. Seery JP,. IFN-Î3 transgenic mice: Clues to the pathogenesis of systemic lupus erythematosus? Arthritis Res 2000; 2: 437-440.
31. Graninger WB, Hassfeld W, Pesau BB, Machold KP, Zielinski CC, Smolen JS,. Induction of systemic lupus erythematosus by interferon-gamma in a patient with rheumatoid arthritis. J Rheumatol 1991; 18: 1621-1622.
32. Bensch KW, Raida M, Mägert HJ, Schulz-Knappe P, Forssmann WG,. hBD-1: A novel β-defensin from human plasma. FEBS Lett 1995; 368: 331-335.
33. Zucht HD, Grabowsky J, Schrader M, et al. Human beta-defensin-1: A urinary peptide present in variant molecular forms and its putative functional implication. Eur J Med Res 1998; 3: 315-323.
34. Bixel G, Kloep S, Butz S, Petri B, Engelhardt B, Vestweber D,. Mouse CD99 participates in T-cell recruitment into inflamed skin. Blood 2004; 104: 3205-3213.
35. Yang Y, Chung EK, Lhotta K, et al.Complement components C4A and C4B in human lupus. In: Zouali M, (ed.) Molecular autoimmunity, NY: Springer, 2005, pp. 85-99.
36. Moreland LW, Gay RE, Gay S,. Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopathol 1991; 60: 412-418.